Biotech
Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight
Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!
Read
Commented by Armin Schulz on June 11th, 2026 | 06:45 CEST
With Novo Nordisk, MustGrow Biologics, and Bayer: Positioning for Two Megatrends of the Decade
Created and published on behalf of MustGrow Biologics Corp.
Two seemingly opposing crises—obesity and food scarcity—are creating major investment opportunities this year. While the obesity epidemic is placing increasing strain on healthcare systems, climate shocks and geopolitical conflicts are threatening global agricultural yields. The biotech sector is addressing both challenges through biological compounds for weight management and crop protection. Demand for effective obesity treatments and sustainable agricultural solutions is rising rapidly. Investors who position themselves early in the beneficiaries of this dual transformation may benefit from above-average returns. This is precisely where the three companies we are taking a closer look at today are positioned: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Carsten Mainitz on June 4th, 2026 | 07:45 CEST
Takeover Fever! BioNxt Solutions, Delivery Hero, and Commerzbank in the Spotlight: How Investors Can Benefit!
The entry of a strategic investor or the prospect of a takeover regularly leads to significant price surges and even massive revaluations. The momentum is enormous; the global market for mergers and acquisitions has reached new records. Especially during periods of technological upheaval, geopolitical realignment, and increasing competitive pressure, companies are increasingly turning to acquisitions to secure growth, resources, or market share. In this context, there are exciting and lucrative developments for investors at BioNxt Solutions, Delivery Hero, and Commerzbank. The investment case for BioNxt Solutions is particularly compelling. The Canadian company aims to bring an alternative to weight-loss injections to market. If successful, this could create a billion-dollar business and attract acquirers. How should investors position themselves?
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by Fabian Lorenz on May 29th, 2026 | 09:40 CEST
A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium
60% in one month, 600% in six months, and 4,000% in one year. Yet there is still no sign of a major correction in SanDisk's stock. Even now, analysts are still raising their price targets significantly and joining the bulls' camp. In contrast, the uranium sector is currently on the sidelines. This offers a chance for contrarian investors. After all, it can really only be a matter of time before the industry is rediscovered as an AI winner. One exciting stock is Standard Uranium. The CEO recently made a strong impression at an investor conference. And what about BioNTech? Investors are disappointed, but analysts are positive. Can the biotech company provide new momentum starting today with new data from its oncology pipeline?
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:15 CEST
+36% in Just a Few Weeks! TeamViewer Impresses Mercedes Formula 1 Team! Will X Corp and BioNxt Solutions Follow?
A 36% gain in just six weeks! Was the market completely wrong about TeamViewer? Is the German software company not an AI loser after all, but instead a potential winner? While it is still too early for a definitive conclusion, recent developments are clearly pointing in the right direction. A comeback candidate could be BioNxt Solutions. Biotech companies are currently overshadowed by the AI boom, but following recent news flow, BioNxt is emerging as a hot buy—and perhaps even a takeover candidate. A potential beneficiary of peace in the Middle East and the reopening of the Strait of Hormuz could be TUI AG. Even without such geopolitical tailwinds, analysts still see further upside potential. Could gains of 50% be possible?
Read
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by André Will-Laudien on May 20th, 2026 | 08:05 CEST
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus!
In recent months, the stock market has focused primarily on high-tech and defence stocks. While this strategy may have worked well for investors in the short term, it has also pushed several life sciences stocks to levels that some consider overly depressed. The Hamburg-based drug discovery company Evotec has lost around 75% of its market value over the past three years, with similar declines seen at BioNTech, Formycon, and BioNxt Solutions. Yet some pipelines are indeed valuable and backed by years of research. For a buyer with deep pockets, this could represent an attractive opportunity, as much of the costly early-stage work has already been completed. We are looking at a sector that has been unjustly forgotten. Where do opportunities lie for risk-conscious investors?
Read
Commented by Fabian Lorenz on May 19th, 2026 | 07:25 CEST
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec!
While gold prices are weakening, Desert Gold shares are in a clear uptrend. And if analysts are to be believed, a tenfold increase is possible. Desert Gold is set to become a gold producer in just a few months and generate strong cash flows. And it does not matter whether gold is trading at USD 4,000 or USD 6,000 per ounce. RENK stock has been upgraded to "Buy." Not because the future outlook has improved, but because the price has plummeted. This means the valuation now offers upside potential again. The growth prospects are quite positive. Meanwhile, analysts have recently noted a lack of growth prospects at Evotec. For many, "Project Horizon" focuses too heavily on cost reduction. But growth is precisely what is expected from a biotech company. And now, the restructuring costs are also to be financed through a convertible bond.
Read